Login to Your Account



Whatcha Say on Pompe, FDA? Biomarin Posts Endpoint Plan

By Randy Osborne
Staff Writer

Wednesday, August 21, 2013

Biomarin Pharmaceutical Inc. has made clearer its Phase III plans for the Pompe disease drug candidate BMN-701, a fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (GAA).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription